Although there was no statistically significant difference in AML1 levels between CML-BC and CML-CP or normal blood samples, noteworthy are the four outlier BC patients whose AML1 levels exceeded the mean +2SD of those of CML-CP samples (Figure 1). This evidence concerns the gene RUNX1 and breast cancer.